Sim, B. Kim Lee
Li, Minglin
Osorio, Manuel
Wu, Yun
Wai, Tint T.
Peterson, Johnny W.
James, Eric R.
Chakravarty, Sumana
Gao, Lixin
Xu, Rui
KC, Natasha
Stafford, Richard E.
Lawrence, William S.
Yeager, Linsey A.
Peel, Jennifer E.
Sivasubramani, Satheesh K.
Chopra, Ashok K.
Filippova, Svetlana
Hoffman, Stephen L.
Article History
Received: 8 December 2016
Revised: 28 April 2017
Accepted: 11 May 2017
First Online: 15 June 2017
Competing interests
: The authors B.K.L.S., M.L., Y.W., T.T.W., L.G., R.X., N.K.C., R.E.S., and S.L.H. are employees of Protein Potential LLC that seeks to commercialize the Ty21a-PA-01 anthrax vaccine. The authors E.R.J., S.C. as well as B.K.L.S. and S.L.H. are employees of Sanaria Inc., which co-develops the Ty21a-PA-01 anthrax vaccine. B.K.L.S. is the owner and president of Protein Potential LLC and received grant funding from NIAID. Author M.O. has a patent “DNA promoters and anthrax vaccines” (US7,758,855; 8,247,225 and EU EP1670505). The authors J.W.P., W.S.L., L.A.Y., J.E.P., S.K.S., A.K.C., and S.F. declare that they have no competing financial interests.